Two Sigma Investments LP Takes $391,000 Position in CureVac (NASDAQ:CVAC)

Two Sigma Investments LP purchased a new position in CureVac (NASDAQ:CVAC - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 114,685 shares of the company's stock, valued at approximately $391,000. Two Sigma Investments LP owned 0.05% of CureVac at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in CVAC. BNP Paribas Financial Markets bought a new position in shares of CureVac during the 4th quarter valued at approximately $585,000. Alyeska Investment Group L.P. lifted its position in CureVac by 25.0% during the fourth quarter. Alyeska Investment Group L.P. now owns 500,000 shares of the company's stock valued at $1,705,000 after purchasing an additional 100,000 shares during the last quarter. Northern Trust Corp grew its stake in shares of CureVac by 98.1% in the 4th quarter. Northern Trust Corp now owns 60,100 shares of the company's stock worth $205,000 after buying an additional 29,759 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of CureVac by 10.3% in the 4th quarter. Geode Capital Management LLC now owns 241,750 shares of the company's stock worth $824,000 after buying an additional 22,491 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. purchased a new stake in shares of CureVac during the 4th quarter valued at about $66,000. 17.26% of the stock is owned by hedge funds and other institutional investors.

CureVac Trading Down 0.5%

NASDAQ:CVAC traded down $0.03 during mid-day trading on Friday, hitting $5.57. 4,834,011 shares of the stock traded hands, compared to its average volume of 800,115. The company has a quick ratio of 6.19, a current ratio of 6.20 and a debt-to-equity ratio of 0.05. CureVac has a 52 week low of $2.37 and a 52 week high of $5.72. The stock has a market capitalization of $1.25 billion, a price-to-earnings ratio of 10.13 and a beta of 2.49. The firm's 50 day moving average is $3.76 and its two-hundred day moving average is $3.48.

CureVac (NASDAQ:CVAC - Get Free Report) last issued its quarterly earnings results on Thursday, May 22nd. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.08). CureVac had a return on equity of 21.98% and a net margin of 20.72%. The business had revenue of $0.94 million during the quarter, compared to analysts' expectations of $4.27 million. On average, equities research analysts predict that CureVac will post 0.72 earnings per share for the current year.

Analysts Set New Price Targets

CVAC has been the subject of several recent research reports. Jefferies Financial Group reiterated a "hold" rating and issued a $5.00 price target (down previously from $7.00) on shares of CureVac in a research report on Friday. JMP Securities reiterated a "market outperform" rating and issued a $10.00 target price on shares of CureVac in a report on Wednesday, May 28th. Finally, UBS Group cut their target price on CureVac from $13.00 to $12.00 and set a "buy" rating on the stock in a research report on Wednesday, April 30th.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.